Introduction
Glioblastoma multiforme (GBM) represents the most common and most aggressive brain tumor and has a poor prognosis (Woehrer et al. 2014) . The etiology of GBM is not completely understood. Exposure to ionizing radiation, hereditary factors (Li-Fraumeni syndrome, neurofibromatosis) , malaria as well as viral infections (herpes simplex virus-6, human cytomegalovirus) have been discussed as possible risk factors (Crawford et al. 2009; Dziurzynski et al. 2012; Lehrer 2010; Madden et al. 2010; Ostrom et al. 2014) .
In addition to surgery, the current GBM therapy is based on temozolomide (TMZ) combined with radiotherapy, which significantly improves progression-free and overall survival times compared to radiotherapy alone (Nagasawa et al. 2012; Stupp et al. 2009; Yang et al. 2014a) . TMZ has been approved to treat GBM and metastatic melanoma. It preferentially methylates and alkylates DNA at N 7 and O 6 positions of guanine residues. TMZ is a prodrug, which is spontaneously activated in aqueous solution to the dacarbazine metabolite, 5-(3-methyl-1-triazeno) imidazole-4-carboxamide (Bei et al. 2010 ). This reaction can take place without involvement of hepatic cytochrome P450 monooxygenase isozymes. DNA O 6 -methylguanine adducts induced by TMZ are repaired by O 6 -alkylguanine-DNA alkyltransferase (AGT), also termed methylguanine methyl transferase (MGMT). High expression of AGT/ MGMT confers resistance to TMZ, whereas methylation of the MGMT promoter, which causes downregulation of MGMT expression, is associated with sensitivity to this drug (Berghoff et al. 2015) . Two other DNA repair mechanisms also contribute to TMZ resistance: mismatch repair (MMR) and base excision repair (BER). MMR recognizes base mismatches and insertion-deletion loops in DNA, while BER repairs TMZ-induced N-based guanine lesions (Marchesi et al. 2007) .
As the majority of GBM patients cannot be cured, there is a desperate quest for novel treatment options in neurooncology, and the willingness for compassionate use of nonapproved medications is high at the side of the patients. In addition to immunological and gene therapeutic approaches Zhai et al. 2015) , phytochemicals might be of some interest as candidates for GBM treatment (Kuete et al. 2014 (Kuete et al. , 2015 Pistollato et al. 2016) .
In addition to their antimalarial activity, artemisinin (ARS) from the Chinese medicinal herb, Artemisia annua L. (Asteraceae), and its derivatives (artesunate, artemether, dihydroartemisinin) also exert remarkable cytotoxic effects toward a wide spectrum of tumor cell lines (Efferth et al. 1996 (Efferth et al. , 2001 (Efferth et al. , 2002 (Efferth et al. , 2003 . Artemisinin (ARS)-type drugs are also active against diverse syngeneic animal tumors (Disbrow et al. 2005; Lai and Singh 2006; Moore et al. 1995) and human xenograft tumors in nude mice (Dell'Eva et al. 2004; Du et al. 2010; Li et al. 2007; Ma et al. 2011) . Activity was also reported against brain tumor cells in vitro and in vivo (Berdelle et al. 2011; Cao et al. 2014; Chen et al. 2015; Efferth et al. 2004b; Huang et al. 2007; Wu et al. 2009 ). Compassionate uses of ARS-type drugs and Artemisia annua preparations for cancer therapy of veterinary and human tumors encouraged the performance of several pilot phase I/II trials in cancer patients (Berger et al. 2005; Breuer and Efferth 2014; Jansen et al. 2011; Krishna et al. 2015; Rutteman et al. 2013; Singh and Verma 2002; Zhang et al. 2008) .
Synergistic interactions between TMZ and artesunate (ART) Karpel-Massler et al. 2014; Zhang et al. 2015) as well as between ionizing radiation and ART (Kim et al. 2006; Reichert et al. 2012 ) raised some interest in ART for compassionate use in GBM patients. Here, we report on the hepatotoxic reaction of the combined treatment of TMZ and ART in a GBM patient, which indicates that the synergism between TMZ and ART observed in vitro might not be limited to cancer cells, but might also harm healthy tissues.
Case report
A 65-year-old patient has been diagnosed with GBM WHO grade 4 on May 26, 2014. Two days later, the tumor in the left central brain has been removed by navigationand ultrasound-based microsurgery and intraoperative radiotherapy (IORT, 20 Gy) within the INTRAGO trial (Giordano et al. 2014) . A small satellite lesion in the left central region was inoperable. She then underwent radiochemotherapy with TMZ (50 mg/m 2 /d p.o.) and externalbeam radiotherapy to a total dose of 60 Gy in 30 fractions. Four weeks after radiochemotherapy, cycling chemotherapy (5 days on, 23 days off) was initiated with 150 mg/ m 2 /d/cycle for the first two cycles and 200 mg/m 2 /d/cycle for subsequent cycles (Stupp et al. 2005) . During radiochemotherapy and chemotherapy, concomitant ondansetron (8 mg/d) was given to prevent nausea.
Exon and transcriptome sequencing of tumor and normal tissue was performed at the National Center for Tumor Diseases (NCT, Heidelberg, Germany), which confirmed the histological diagnosis of GBM. In total, 65 nucleotide substitutions, three focal and 17 larger copy number changes were found. The promoter region of the MGMT gene was methylated.
The patient also received anticonvulsive medication due to episodes of symptomatic epilepsy (focal seizures), including levetiracetam (1000 mg/d starting dose, escalated to 2750 mg/d), lorazepam (1 mg/d p.r.n.) and clobazam (5 mg/d p.r.n.).
Starting September 20, 2015, the patient voluntarily decided to additionally start off-label treatment with ART capsules (200 mg/d) and Coptis-Kush decoct (0.5 g Rhizoma Coptidis chinensis; 3.0 g Herba Siegesbeckiae orientalis; 6.0 g Herba Artemisiae scopariae H; 2 g Radix Dictamni dasycarpi; 20 doses). Coptis-Kush intake was stopped 2.5 weeks later, and ART intake on October 20, 2015.
As outlined in Table 1 , plasma liver enzymes increased after intake of ART and Coptis-Kush. Leukocyte counts and especially monocytes were continuously decreased since August 2015 and remained below the normal range even after cessation of ART/Coptis-Kush, indicating that this leukopenia may be unrelated to ART/Coptis-Kush.
Symptoms appearing at that time were weight loss, heartburn, left thoracic sting independent of stress, nausea, adynamia, fatigue, and depressive mood. After ceasing ART and Coptis-Kush intake, liver parameters gradually returned back to normal. Presently, the patient feels well and all symptoms vanished.
Of note, over the whole episode of hepatic enzyme elevation and subsequent clinical deterioration, serial MRIs revealed no signs of progressive disease regarding the brain tumor. The tumor did not progress even 1 year after intake of ART.
Discussion
Here, we report a case of hepatotoxicity in a GBM patient treated with TMZ, ART and Chinese herbs. It is unclear whether one of these two drugs alone are responsible for this toxic reaction or whether it developed only by their combination. However, the evident hepatic enzyme elevation and clinical deterioration immediately after initiation of treatment suggests that ART and/or Chinese herbs might have been at least eliciting events.
TMZ's tolerability represents a considerable concern for its use. Myelotoxicity is a well-known severe adverse effect of TMZ (anemia, drop of hemoglobin levels, neutropenia, thrombocytopenia). Further side effects include nausea, vomiting, loss of appetite, constipation, convulsions, diarrhea, skin rash, fatigue, weakness, dizziness, blurred vision, insomnia, headache, and very rarely, alopecia. Hepatotoxicity did not play a significant role during official approval as cancer drug. During the postmarketing phase, however, numerous cases with severe liver injury have been reported (Table 2 ) (for review, see also Dixit et al. 2011 ). The range of toxic reactions ranged from elevation of liver transaminases to jaundice, cholestatic hepatitis, steatohepatitis, hepatic encephalopathy, and hepatitis B virus reactivation (Table 2) .
TMZ reactivates hepatitis B viruses (Fujimoto et al. 2012; Purchiaroni et al. 2014) . Furthermore, prior malaria infections might increase the risk of GMB development (Lehrer 2010) . The patient presented here experienced several malaria infections many years ago. It is unknown whether TMZ reactivates or stimulates a still unknown, carcinogenic virus transmitted by Anopheles mosquitos that also contribute to hepatotoxicity.
ART seems to be a rather safe drug. Large clinical studies and meta-analyses with many thousands of malaria patients did not show serious side effects, although there is a paucity of large-scale clinical trials suitable to detect rare, but significant toxicity (Efferth and Kaina 2010) . Toxicity studies in vitro and in vivo (mice, rats, rabbits, dogs, monkeys) provided hints for potential neurotoxicity, embryotoxicity, genotoxicity, hemato-and immunotoxicity, cardiotoxicity, nephrotoxicity, and allergic reactions. Long-term availability rather than short-term peak concentrations of artemisinins may cause toxicity. Rapid elimination of artemisinins after oral intake represents a relatively safe route of administration compared to delayed drug release after intramuscular injection. This explains why considerable toxicities were found in the majority of animal experiments, but not in human studies. Moreover, there are drug-related differences, i.e., intramuscular application of artemether or arteether bears some toxic potential, but not ART, which is safe and gives good profiles after i.m. administration in severe malaria. This fact may be important for determining dose-limiting toxicities for cancer.
Large meta-analyses with many thousands of malaria patients reported elevated liver enzymes in 0.9 % of all cases (Ribeiro and Olliaro 1998) . Severe liver injury was reported in two cases after consumption of ARS-containing herbal supplements (CDC 2009; Kumar 2015) . According to the current literature, the hepatotoxic risk is much higher for TMZ than for ART. This conclusion is also supported by animal experiments, which described liver enzyme changes upon treatment with ARS-based drugs, but no severe acute liver injuries (Table 3) (Berger et al. 2005; Breuer and Efferth 2014; Ericsson et al. 2014a; Jansen et al. 2011; Michaelsen et al. 2015; Rutteman et al. 2013; Singh and Verma 2002; Zhang et al. 2008) . Hepatotoxicity represents a rare event upon combined treatment with TMZ or ART, although more cases of hepatotoxicity are documented for TMZ than for ART. It is possible that drug-drug interaction may synergistically increase the low hepatotoxic potential of both drugs applied alone. Hepatotoxicity by ART is extremely rare in malaria, but occurred in the present case of GBM. This might be due to the fact that concentrations of ART used for malaria treatment (usually 50 mg/day for 3-4 days) are lower than those used for cancer therapy (in the present case: 200 mg/d for 4 weeks). Higher ART doses may increase the risk of toxic reactions of the body. While the exact reasons for the hepatotoxicity of the TMZ/ART combination in the patient presented here are unknown, several mechanisms might have account for this hepatotoxic reaction:
1. Drugs affect the activity of drug metabolizing phase I and II enzymes, e.g., cytochrome P450 monooxygenases (CYPs) and glutathione S-transferases (GSTs). 2. Gene polymorphisms increase drug activity toward tumors and toxicity toward normal tissues. 3. A drug combination regimen damages DNA at different sites leading to increased DNA damage in normal organs.
Although the activation of TMZ as prodrug to the active metabolite occurs spontaneously in aqueous solution, additional metabolization by CYPs in the liver may be possible. A recent study reports on factors associated with severe hematological toxicity of GBM patients treated with standard therapy (TMZ + radiation) (Lombardi et al. 2015) . Among different other factors, polymorphisms in CYP genes predicted severe myelotoxicity. It can be speculated that CYP polymorphisms also increase the hepatotoxic potential of TMZ in these patients. Polymorphisms in other genes (MGMT, NQO1, GSTP1) were related to an increased risk of myelotoxicity in a subset of GBM patients (Armstrong et al. 2009 ). It can be speculated that specific gene polymorphisms also contribute to TMZ-induced hepatotoxicity. An association of TMZ-induced toxicity to DNA damage and repair has not been reported as of yet.
In contrast to TMZ, ARS derivatives are metabolized in the liver to the active metabolite, dihydroartemisinin. ARS, ART, artemether and dihydroartemisinin inhibit the enzymatic activity of several recombinant CYP enzymes (CYP1A2, 2B6, 2C19, and 3A4) (Ericsson et al. 2014b) . A high risk of interaction in vivo could be predicted, if ARStype drugs are co-administered with other drugs that are CYP1A2 or 2C19 substrates. Subjects with CYP2AG*1B, which is responsible for ultrarapid ART metabolism, revealed more adverse drug reactions including elevated liver enzymes (Yusof and Hua 2012) .
Microarray analyses of tumor cell lines revealed that the expression of several DNA damage response and repair genes significantly correlated with cellular response of ARS-type drugs in these cell lines, e.g., ERCC5, FEN1, HMG1, HMF17, LIG1, RPS3, UNG, and UBE2A (Efferth et al. 2002 (Efferth et al. , 2003 . ART may induce DNA damage by cleaving its endoperoxide moiety, which leads to reactive oxygen species-or carbon-centered radical-mediated DNA damage. ART dose-dependently induced DNA breaks in the comet assay and induced the expression of γ-H2AX, which is considered as marker for DNA double-strand breaks . Polymerase β-deficient cells were more sensitive to ART than wild-type cells, indicating that DNA lesions are repaired by BER. Irs1 and VC8 cells defective in homologous recombination (HR) by XRCC2 and BRCA2 inactivation, as well as XR-V15B cells defective in non-homologous end joining (NHEJ) by Ku80 inactivation of Ku80, were also more susceptible to ART than the corresponding wild-type cells .
ART is a powerful inducer of oxidative DNA damage. It generates formamidopyrimidine DNA glycosylase-sensitive sites and forms 8-oxoguanine and 1,N 6 -ethenoadenine. In human LN-229 glioblastoma, ART-induced oxidative DNA damage was attenuated by the radical scavenger, N-acetyl cysteine. Oxidative DNA damage caused DSBs as determined by γ-H2AX foci. Knockdown of Rad51 by siRNA and inactivation of DNA-PK strongly sensitized glioma cells to ART. These data also indicate that both HJ and NHEJ pathways contribute to ART-induced DSB repair. ART provoked DNA damage response that was characterized by phosphorylation of ATM, ATR, Chk1, and Chk2 (Berdelle et al. 2011) . Our initial findings on ART-induced DNA damage were confirmed for other artemisinin derivatives (Alcantara et al. 2013; Park et al. 2015) .
The DNA damaging properties of ARS-type drugs may also play a role for their toxicity toward normal cells. In mice, ART caused DNA damage in liver cells and spermatozoa. It affected the antioxidant stress response (depletion of glutathione, inhibition of superoxide dismutase, and increase of lipid peroxidation) (Aquino et al. 2011 (Aquino et al. , 2013 Singh et al. 2015) . These data speak for potential genotoxicity in vivo.
Conclusions and perspectives
The compassionate GBM therapy combining ART and Chinese herbs with standard chemotherapy is not recommended, as indicated by the present case of hepatotoxicity. ARS-type drugs confer ferrous iron-mediated oxidative damage leading to DNA damage in tumor cells (Efferth 2015; Efferth et al. 2004a; Kelter et al. 2007; Ooko et al. 2015) . As the liver is a major iron-storing organ in the human body, hepatotoxicity by ARS and its derivatives may be a special concern. In a pilot I/II trial, we reported that ART monotherapy is safe and efficient in cervix carcinoma (Jansen et al. 2011) . ART plus surgery was also safe and efficient to treat colon carcinoma (Krishna et al. 2015) . In another phase I trial with veterinary tumors, we found several side effects (fever, anemia, thrombocytopenia, and gastrointestinal toxicity), but not hepatotoxicity (Rutteman et al. 2013) . Kumar (2015) Severe and complicated malaria Intravenous ART 102 Elevated hepatic enzyme levels (49 %) Twomey et al. (2015) While no reports on the hepatotoxicity of Coptis chinensis have been published, this herb may rather act in a hepatoprotective manner (Choi et al. 2013 ). The same is true for Artemisia scoparia Janbaz 1993, 1994; Wang et al. 2013b) . Although these two drugs have been reported to be hepatoprotective, they did not prevent the increase of hepatic enzyme activities in the GBM patient presented here, which raises the question about their activity. Nothing is known about the potential liver toxicity of Siegesbeckia. However, Dicramnus dasycarpus induces liver injury . Therefore, it cannot be excluded that this plant contributed to the hepatotoxicity described in the present case report. Even the other medications used in GBM management could be considered for their toxic potential. Valproic acid and Levetiracetam (lacosamide) have been also reported to exert hepatotoxic effects (Gerstner et al. 2008; Sunwoo et al. 2015) .
In addition to TMZ and ART, the patient ingested a variety of herbs and, moreover, multiple antiepileptic and sedative drugs. As many of these drugs are known to be hepatotoxic, the appearance of fulminant hepatotoxicity is not highly surprising and it is difficult to dissect the contribution of the different medications for the outbreak of acute liver toxicity. Compassionate intake of such complex additional medications together with anticancer drugs can be expected to cause severe side effects not only in GBM patients, but also in patients treated with different therapeutic regimen than TMZ. Controlled clinical trials have to clarify how frequently hepatotoxicity may occur upon GBM treatment with combinations of TMZ, ART and other herbal drugs. This case of severe hepatotoxicity also illustrates that unexpected toxicity can occur not only with non-approved drugs, but also with novel combinations of clinically established drugs.
In conclusion, the presented case can be taken as a hint for the possible consequences of compassionate use of non-approved drugs or unproven drug combinations. Drug therapy should always be in accordance to the guidelines of good clinical practice and new therapies or combinations evaluated within controlled clinical trials. Concepts to apply marketed and otherwise safe drugs used for other non-cancer indications for GBM therapy should be handled with care to avoid unexpected severe toxicities (Kast et al. 2013 .
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